Clinical Trial Update: Empagliflozin Effect on Glucose Toxicity [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating empagliflozin for glucose toxicity in type 2 diabetes mellitus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Type2 Diabetes Mellitus | Phase 4 | Status: WITHDRAWN